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SUMOylation has emerged as an important regulatory mechanism for protein
function. SUMO-specific proteases (SENPs) are essential for removing SUMO from
conjugated proteins in many different systems, but the physiological functions of
SENPs are poorly understood. STAT5 (Signal Transducer and Activator of
Transcription 5) plays a critical role in the development of lymphoid cells. However,
it is not known whether STAT5 is regulated by the SUMOylation pathway. Here, we
showed that SUMOylated STAT5 is accumulated in SENP1-/- lymphoid precursors.
SENP1 deficiency results in severe defects in early T and B cell development,
similar to that observed in mice harboring a complete inactivation of STAT5.
Because STAT5 is SUMOylated and acetylated at the same lysine residue, SENP1
deficiency blocks STAT5 in the SUMOylation state, resulting in diminished STAT5
acetylation and phosphorylation, and defective lymphoid development. Thus, our
results reveal a novel function of SENP1 in the regulation of early lymphoid
development via an acetylation/SUMOylation switch in STAT5.
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INTRODUCTION

SUMO (small ubiquitin-like modifier)

In eukaryotes, protein function is tightly regulated by multiple mechanisms,
such as control of transcription and translation, and post-translational modifications.
Over the past decade, posttranslational modifications of proteins, including
phosphorylation, methylation, acetylation and ubiquitination, have been extensively
studied. SUMOylation, a posttranslational modification of proteins by SUMO, has
emerged recently as an important regulatory mechanism in cell physiology.
SUMO was discovered in the mid 1990s. The Saccharomyces cerevisiae
SMT3 gene was first described as a suppressor of MIF2 protein required for mitotic
spindle integrity in 1995 (1). In 1996, using the death domain in the cytoplasmic tail
of Fas/APO-1 and TNF receptor 1 as bait in the yeast two-hybrid system, our
laboratory reported the isolation of a novel death domain-interacting protein, Sentrin
(later re-named as SUMO-1), which exhibited homology to ubiquitin, Nedd8 and
SMT3. Interestingly, Overexpression of Sentrin protected cells from both antiFas/APO-1 and TNF-induced cell death. However, the mechanism by which Sentrin
inhibits the cell death signaling remains to be elucidated (2). At the same time, five
other groups identified different human and mouse homologs of S. cerevisiae SMT3,
and called them different names, including PIC1 (PML interacting protein 1), GMP1
(GAP-modifying protein 1), Ubl1 (ubiquitin-like protein 1), SUMO-1 (smallubiquitin-related modifier) (3-6), and human HSMT3 (later called human SUMO-2)
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(7).

Although human SUMO-1 has only a low sequence similarity of 18% to

ubiquitin, NMR structure analysis revealed that SUMO-1 and Ubiquitin display
similar 3-D structure (8). The C-terminal diglycine residues of both SUMO and
ubiquitin are required for formation of an isopeptide bond with the -NH2 group of
lysine residue in targeted proteins.
Four SUMO homologs have been indentified in mammalian cells. SUMO-1
shares 47% similarity at the protein level with SUMO-2 and 3, whereas SUMO-2
and 3 are 95% identical. In contrast to SUMO-1, SUMO-2 and SUMO-3 have a
consensus SUMOylation site at their N-terminal region and can form poly-SUMO
Chains (9). SUMO-1, 2 and 3 are ubiquitously expressed in all tissues, while SUMO4 expression is limited to immune tissues and kidney (10, 11). The conjugation of
SUMO-4 to substrates in vivo still remains obscure.

The SUMOylation pathway

All SUMO proteins are synthesized as immature forms that must be
processed to expose the C-terminal di-glycine motif to generate the mature forms.
This processing is carried out by the sentrin/SUMO-specific protease (SENP) family.
The mature form of SUMOs is activated by a SUMO-activating enzyme (E1), a
heterodimer containing SAE1 (SUMO-activating enzyme subunit 1) and SAE2,
transferred by a SUMO-conjugating enzyme (E2) UBC9, and in some cases, to a
SUMO protein ligase (E3) that catalyzes the formation of an isopeptide bond
between the C-terminal carboxy group of SUMO and the ε-amino group of lysine in

2

protein substrates. Lysine residues subject to SUMO modification are usually found
within a SUMO modification consensus motif, ψKXE/D (where ψ is a large
hydrophobic residue and X is any residue). Currently, several SUMO E3 ligases
have been characterized, including PIAS (protein inhibitor of activated STAT)
proteins, the nucleoporin RanBP2 and the polycomb protein Pc2 (12, 13).
The covalent modification of proteins by SUMO can be reversed by SENPs,
as illustrated in Figure 1. Thus, SENP regulates SUMOylation via (1) its C-terminal
hydrolase activity required for removing C-terminal amino acids from SUMO to
reveal the diglycine residues important for conjugation to SUMO substrates and/or
(2) its isopeptidase activity that is essential for removing SUMO from conjugated
substrates. Two yeast SENPs, including Ulp1 and Ulp2/Smt4 were characterized first
(14, 15). Ulp1 has both the C-terminal hydrolase activity and the isopeptidase
activity, while Ulp2 possesses only the isopeptidase activity.
In 2000, our laboratory cloned the first mammalian Sentrin/SUMO-specific
protease (SENP1), which is distantly related to the yeast Ulp1 (16). Currently, six
SENPs have been identified in mammalian cells. They can be divided into three
subfamilies on the basis of their sequence homology, cellular localization and
substrate specificity (17-19). The first subfamily, consisting of SENP1 and SENP2,
can process either SUMO-1 or SUMO-2/3-conjugated proteins. The second
subfamily contains SENP3 and SENP5, which prefer SUMO2/3 as substrates and are
localized in the nucleolus. The third subfamily including SENP6 and SENP7 also
favors SUMO2/3-modified substrates.
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Figure 1. SUMOylation vs deSUMOylation. Target protein can be SUMOylated
by SUMO E1, E2 and E3 ligases, and SUMO-conjugated protein can be
deSUMOylated by Sentrin/SUMO-specific proteases (SENPs) to remove SUMO
from target.
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Biological Function of SUMO-specific proteases

SUMOylation has been shown to play key roles in regulating diverse cellular
processes, including transcription, DNA repair, cell-cycle progression and signal
transduction from yeast to human (13, 19). SENPs are essential for reversing
SUMOylation in many different systems; however, the physiological significance
and in vivo functions of SENPs are poorly understood.
In an attempt to understand the role of SENP1 in development, Yamaguchi
et al. generated mice from an ES cell line with a retroviral vector that was randomly
inserted into the enhancer region on the SENP1 gene (20). This random insertion
reduced expression of the SENP1 transcript, resulting in embryonic lethality between
E12.5 and E14.5. Interestingly, the mutation caused the accumulation of the
SUMOylated forms of a number of proteins both in the fetus and placenta. These
data suggest that SENP1 is important for regulating the levels of SUMOylated
proteins during embryonic development. However, the exact molecular mechanism
by which SENP1 contributes to development is not clear.
Because SENP1 expression in Yamaguchi’s mouse model is partially
blocked, our laboratory generated complete SENP1 knockout mice to further
evaluate the contribution of SENP1 in development. SENP1 knockout (KO) mice
were generated from an embryonic stem cell line with a gene trap vector that was
inserted into the mouse SENP1 open reading frame at codon 310 (21). This insertion
completely blocked SENP1 expression. SENP1 deficiency caused embryonic
lethality between E13 and E15, due to severe fetal anemia (21). SENP1 controls EPO
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production by regulating the stability of hypoxia-inducible factor 1 (HIF1). In the
absence of SENP1, hypoxia induced HIF1 SUMOylation, thereby leading to
HIF1 ubiquitylation and proteasomal degradation.
Recently, another group created SENP1 KO mice based on a Cre–loxP
system (22). SENP1lox/lox mice were crossed with β-actin–Cre mice to mediate a
recombination in vivo, resulting in a complete deletion of SENP1 exon 5 and exon 6
and a frameshift of the downstream catalytic domain. This global deletion of SENP1
leads to embryonic lethality between embryonic day 13.5 and postnatal day 1, and
anemia (22). SENP1 controls GATA1 activation and erythropoiesis through
deSUMOylation of GATA1.
Two groups have independently uncovered the role of SENP2 and the
importance of SUMOylation in development. Chiu and colleagues generated SENP2
KO mice using the Cre-LoxP system and demonstrated that SENP2-/- mice exhibited
embryonic lethality between E10.5 to E11.5, due to a placenta defect (23). In the
absence of SENP2, SUMOylated Mdm2 accumulates in the nucleus, where it is
unable to promote p53 degradation. Accumulation of p53 in trophoblast progenitors
causes cell growth arrest and subsequent defect in placental development. Our
laboratory generated SENP2 KO mice using a gene trap vector inserted into intron
10 of SENP2 genomic DNA and disrupted the transcript of the catalytic domain of
SENP2 (24). Deletion of the murine SENP2 gene causes embryonic lethality at E10,
due to a profound defect in the cardiac development (24). The expression of Gata4
and Gata6 genes is essential for cardiac development, and is regulated by occupancy
of Pc2/CBX4, a polycomb repressive complex 1 (PRC1) subunit, on their promoters.

6

In the absence of SENP2, SUMOylated Pc2/CBX4 accumulates and Pc2/CBX4
occupancy at the promoters of PcG target genes is markedly increased, leading to
repression of Gata4 and Gata6 transcription (24). The phenotypic differences
observed in these two SENP2 KO mouse models are difficult to explain. It is
possible that the KO strategies used to inactivate the SENP2 gene may also
contribute to the difference in phenotypes observed. Future studies using tissue
specific gene-targeting (Cre/loxP system) to inactivate the SENP2 gene are needed to
further characterize the role of SENP2 and its target genes in development.
A more recent study by Dou et al. has revealed that SENP6 regulates the
SUMOylation status of RPA70, which plays a critical role in DNA repair through
homologous recombination (HR) (25). SENP6-depleted cells exhibited the typical
phenotypes of DNA damage response, including the accumulation of γ-H2AX foci,
activated cell cycle check points (phosphorylated Chk1 and Chk2) and defective cell
cycle progression in both S phase and G2/M phases, correlating with the
accumulation of SUMOylated RPA70. Biochemical experiments further indicated
that RPA70 SUMOylation serves as HR mediator to facilitate recruitment of Rad51
to the DNA damage foci to initiate DNA repair through HR. This study clearly
demonstrates the role of SENP6 in regulating RPA70 SUMOylation and HR.
However, suppression of SENP6 accumulated DNA damage foci, suggesting that
SENP6 is also essential for maintaining genomic stability, possibly through
regulation of DNA replication or telomere elongation/maintenance. Further
investigations are required to clarify this important issue.
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Molecular mechanisms by which SUMOylation regulates transcription

SUMOylation plays a critical role in regulating gene expression by various
mechanisms. Instead of single-site action, many proteins are dynamically modified at
multiple sites by different modifications, including phosphorylation, acetylation,
ubiquitination, and sumoylation. This phenomenon is known as multisite
modification (26). Hietakangas and others identified a PDSM (phosphorylationdependent sumoylation motif), containing a SUMO consensus site and an adjacent
proline-directed phosphorylation site (ΨKxExxSP) (27, 28). This highly conserved
motif regulates phosphorylation-dependent sumoylation of multiple substrates, such
as heat-shock factors (HSFs), GATA-1, and myocyte enhancer factor 2 (MEF2).
Thus, SUMOylation can affect other modifications or function of proteins.
Since a lysine residue can be a target of different posttranslational
modifications, SUMOylation can block alternative lysine-targeted modifications
such as ubiquitination, methylation or acetylation. Ubiquitination and proteasomemediated degradation of IκBα are known to be crucial for activation of NF-κB. In
1998, Hay’s group demonstrated that IκBα is SUMOylated on K21, which is also
targeted by ubiquitination (29). SUMOylated IκBα cannot be ubiquitinated and is
therefore resistant to proteasome-mediated degradation. Thus, by blocking
ubiquitination, SUMOylation creates a privileged pool of IκBα that is resistant to
signal-induced degradation (29). Transcriptional activity of transcription factors,
sush as SP3 and MEF2A, can be regulated by interplay between SUMOylation and
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acetylation on the same lysine residue (30, 31). Interestingly, an acetylationsumoylation switch on MEF2 is further regulated by its phosphorylation (31).
Many transcription factors, coactivators, or corepressors are SUMOylated,
resulting in alterations of their cellular localization, stability, and interaction with
binding partners. In most cases, SUMOylated proteins suppress transcription,
possibly due to their interaction with co-repressors. Therefore, blocking SUMO
conjugation to substrates by lysine-to-arginine mutation of SUMOylation sites or by
overexpression of SENPs can increase the transcriptional activity of transcription
factors (32).
An increasing number of studies support the notion that SUMOylation of
proteins alters their interaction with binding partners, in particular those having a
SUMO-interaction motif (SIM) (33, 34). The SIM mediates non-covalent
interactions between SIM-containing proteins and SUMO. This motif consists of the
short hydrophobic peptide sequence V/I/L-V/I/L-X-V/I/L or V/I/L-X-V/I/L-V/I/L
and in some cases, are preceded, or followed, by a stretch of acidic amino acids. A
recent study by Glass group has highlighted the importance of SIM in regulation of
Toll-like receptors (TLRs) in macrophages (35). Transcriptional activation of many
TLR-responsive genes is archived by an initial de-repression step that nuclear
receptor co-repressor (NCoR) complexes are actively removed from the promoters of
target genes. Ligand-dependent SUMOylation of liver X receptors (LXRs) inhibits
TLR4-induced transcription potently by preventing the NCoR clearance step. The
study has demonstrated that SUMOylated LXRs block NCoR turnover by binding to
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a conserved SUMO2/SUMO3-interaction motif in CORO2A, a component of the
NCoR complex, and preventing nuclear actin recruitment.
Another example of SIM is SUMO-targeted ubiquitin Ligase (STUbL) family
of proteins, which selectively ubiquitinates sumoylated proteins and proteins
containing SUMO-like domains (SLDs). STUbL recruitment to sumoylated/SLD
proteins is mediated by tandem SUMO interaction motifs (SIMs) within the STUbLs
N-terminus (36, 37). Although the roles of STUbLs in regulating transcription and
DNA repair in yeast have been documented, little is known about their functions in
mammalian cells.

STAT proteins

It is well known that cytokines play a central role in the regulation of the
immune system. Three key families of transcription factors that are widely used
downstream of cytokine-mediated to control gene expression include the signal
transducer and activator of transcription (STAT) family of proteins, nuclear factorkB

(NF-kB)

and

SMA

(small

body

size)-and

MAD

(mothers

against

decapentaplegic)-related proteins (SMADs) (38). In 1992, STAT1 and STAT2 were
the first members of STAT proteins identified as mediators of the cellular response
to interferons (IFNs) (39, 40). Currently, seven mammalian STATs have been
identified, including STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and
STAT6, encoded by different genes (41). In the human genome, Stat1 and Stat4
genes are clustered together on chromosome 2, and Stat3, Stat5a and Stat5b genes
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are clustered together on chromosome 17, whereas Stat2 and Stat6 genes are
clustered together on chromosome 12 (42). All STAT proteins share six structural
regions: an N-terminal domain (ND), a coil-coil domain (CC), a DNA-binding
domain (DBD), a linker domain (L), a Src homology 2 (SH2) domain, and a
transcriptional activation domain (TAD) at the carboxy (C) terminus. A single
tyrosine residue (Y700) located in the TAD is required for STAT activation.
The JAK (Janus kinase)-STAT signaling pathway consists of three main
components: a receptor, JAK and STAT. Tyrosine kinases of the JAK family,
including tyrosine kinase 2 (TYK2), JAK1, JAK2 and JAK3, are physically
associated with the intracellular domains of many cytokine receptors. After cytokines
bind to their cognate receptor on the cell surface, JAKs are activated and they then
phosphorylate the cytoplasmic tails of the cytokine receptors at tyrosine residues,
leading to recruitment and phosphorylation of STATs. Subsequently, activated
STATs in the cytoplasm translocate to the nucleus, where they bind to specific DNA
sites and activate the transcription of their specific genes.

Regulation of STATs by acetylation

In eukaryotic cells, chromatin is composed of DNA, histones and other
nuclear proteins, and can be broadly classified into condensed heterochromatin and
decondensed euchromatin. DNA in heterochromatin is inaccessible to enzymes for
processes such as transcription, recombination and DNA repair while euchromatic
DNA is accessible and active for these processes. Constitutive heterochromatin is
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formed at repetitive DNA sequences, such as pericentromeres and telomeres,
whereas the formation of facultative heterochromatin is inducible, and is often
associated with a change in cell phenotype.
A variety of modifications at the N-terminal tail of histones, such as
acetylation, methylation and phosphorylation form the basis of the “histone code”,
which can act as either repressive or active marks (43). These histone modifications
recruit distinct protein complexes that affect chromatin structure. For histone lysine
methylation (mono-, di-, and tri-methylation), H3 methylated at lysine-4 (K4), K36,
and K79 are enriched in active chromatin, whereas methylation of H3-K9, H3-K27,
and H4-K20 is responsible for heterochomatic silencing (44-46). Acetylation of
histones H3 and H4 is associated with transcriptionally active chromatin. The role of
histone lysine modifications in transcription regulation is well established; however
modifications of non-histone proteins, in particular by acetylation, have recently
emerged as an important mechanism of epigenetic regulation in transcription (47).
The histone acetyltransferases CREB-binding protein (CBP)/p300 have been
shown to interact with various STAT family members within both the C-terminal
TAD and N-terminal domain, and promote STAT-mediated transcription (48-51).
This raised the possibility that STATs could be modified by acetylation. Several
studies have been reported concerning the acetylation of different STAT family
members. STAT6 was the first STAT protein shown to be a target of acetylation
(52). STAT1 is modified by acetylation at lysines 410 and 413. Interestingly, a
phosphorylation-acetylation switch regulates STAT1 signaling (53, 54). Recent
studies by Chin and colleagues reveal that STAT3 is acetylated at lysine 685 by
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p300/CBP and that this modification is essential for STAT3 to form stable dimers
and to activate transcription (55), whereas STAT2 acetylation on Lys390 regulates
STAT2:STAT1 interaction (56), and STAT5 acetylation is required for dimerization
(57). These studies clearly indicate that modification of STATs by acetylation is
critical for regulating the JAK-STAT signaling pathway.

Regulation of STATs by PIAS (Protein Inhibitor of Activated STAT)

The mammalian protein inhibitor of activated STAT (PIAS) family of
proteins was initially identified as negative regulators of STAT signaling (58, 59).
The PIAS family includes PIAS1, PIAS3, PIASx (also known as PIAS2) and PIASy
(also known as PIAS4). Except for PIAS1, each PIAS protein has two isoforms.
Biochemical studies have revealed that more than 60 proteins, most of them
transcription factors, can be regulated by members of the PIAS family through
multiple mechanisms (38). First, a PIAS protein might block the DNA-binding
activity of a transcription factor. A study by Shuai’s group showed that Pias1
Deletion enhanced the antiviral activity of IFN-- or IFN-. As a result, Pias1-/mice showed increased protection against pathogenic infection. This is probably
because PIAS1 selectively regulates a subset of IFN-- or IFN--inducible genes by
interfering with the recruitment of STAT1 to the gene promoter (60). Secondly, a
PIAS protein might recruit other co-regulators, such as histone deacetylases
(HDACs), to repress transcription. For example, Shuai’s group has recently reported

13

that PIAS1 binding to the Foxp3 promoter leads to recruitment of DNA
methyltransferases and heterochromatin protein 1 for epigenetic modifications (61).
Pias1 deletion resulted in promoter demethylation, reduced histone H3 methylation
at Lys9, and enhanced promoter accessibility. As a result, Pias1-/- mice showed an
increased natural CD4(+)Foxp3(+) regulatory T (T(reg)) cell population and were
resistant to the development of experimental autoimmune encephalomyelitis (61).
Thirdly, a PIAS protein might repress transcription by promoting the sumoylation of
a transcription factor. Lastly, PIAS proteins might repress transcription by altering
the localization of transcription factors. Despite their inhibitory roles in
transcriptional regulation, PIAS proteins can regulate positively several transcription
factors. For example, PIAS3 activates, whereas PIASy represses, the transcriptional
activity of SMAD3 (62).

Regulation of STATs by SUMOylation

PIAS proteins have been shown to function as SUMO-specific E3 ligases
(63). This raises the possibility that STATs might be regulated by the SUMOylation
pathway. Several groups have reported that STAT1 is SUMOylated on Lys703 in an
overexpression system and that its SUMOylation can be greatly enhanced by PIAS
proteins (63, 64). However, the in vivo function of SUMOylation in the regulation of
STAT1 activity remains unknown. In addition, it is not known whether other STAT
proteins can be modified by SUMO.
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Biological function of STATs

To elucidate the in vivo function of STAT proteins, all STAT genes have
been gene-targeted in mice. The phenotypes of these mice reveal distinctive
functions of STAT genes and the importance of these genes in regulating the
development and function of the immune system (65-68).

STAT1

IFNs are known to regulate cellular antiviral, antiproliferative and
immunological responses. IFNs include two types of IFNs, Type-I (IFN-α and IFNβ) and Type-II (IFN-γ), which bind to bind to the Type-I IFN receptor and the TypeII IFN receptor, respectively. IFN-α/β activates both STAT1 and STAT2, whereas
IFN-γ stimulates the tyrosine phosphorylation of STAT1 but not STAT2. STAT1−/−
mice are viable and fertile, but highly susceptible to microbial and viral infections
and tumor formation due to severely impaired IFN responses (69, 70). In addition to
IFNs, Stat1 can be activated by many growth factors including IL-6, IL-10, growth
hormone and thrombopoietin. However, no major developmental defects were
observed in STAT1−/− mice involving to non-IFN signaling. Thus, STAT1 is
essential for the IFN-dependent signaling pathways.
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STAT2

As discussed above, the major function of STAT2 is involved in IFN-α/β
signaling. STAT2 knockout mice are fertile and viable but exhibit a number of
defects in immune response, including an increased susceptibility to viral infection
and the loss of IFN-α/β responsiveness (71).

STAT3

STAT3 can be activated by IL-6 family members, IFNγ, IL-10, and
granulocyte-colony stimulating factor (G-CSF). Targeted deletion of STAT3 causes
embryonic lethality at E7.5, suggesting that STAT3 plays a role during early
embryogenesis (72). Increasing evidence suggests that STAT3 plays critical roles in
the immune system, including inhibition of macrophage inflammatory signaling,
control of dendritic cell differentiation, regulation of steady state and emergency
granulopoiesis and regulation of B cell development (73-76). For example, Akira’s
group generated STAT3 conditional KO mice by breeding of mice carrying a loxPflanked Stat3 allele with LysMcre mice in which the Cre-recombinase is expressed
under control of the murine lysozyme M gene regulatory region (73). In these nice,
STAT3 is deficient specifically in macrophages and neutrophils. The mutant mice
exhibit increased production of inflammatory cytokines such as TNF-α, IL-1, and
IFN-γ and impaired suppressive effects of IL-10 on inflammatory cytokine
production from macrophages and neutrophils (73).
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It was initially thought that after activation by professional antigen-presenting
cells (APCs), naive CD4+ T cells were able to differentiate into effector cells, which
could be divided into two subsets, T helper 1 (Th1) and T helper 2 (Th2) cells based
on their cytokine-expression profiles and immune-regulatory function (77). Recently,
three other subsets have been identified. The first new subset of TH cells is CD4+
CD25+ regulatory T cells (T reg cells), which play a central role in the maintenance
of immune tolerance (78-80). Dong and colleagues have characterized two other
novel TH-cell subsets, including follicular helper T cells and IL-17-producing CD4+
T (TH17) cells (also identified by Weaver’s group), which have crucial roles in
immune regulation (81, 82). Interestingly, STAT3 is crucial for the differentiation of
the TH17 cells (83). In contrast, activation of STAT5 is a critical factor in the
induction and maintenance of FOXP3 expression in Treg cells (84).

STAT4

IL-12 promotes naïve CD4+ T cells (Th0 cells) to differentiate into Th1 cells,
which secrete IL-2 and IFN-γ, and play a critical role in cellular-mediated immunity.
STAT4 is activated by IL-12. STAT4-/- mice are viable and fertile. However, these
mice showed impaired Th1 differentiation, IFN-γ production and cell-mediated
immunity (85, 86), similar to the phenotypes of mice lacking IL-12 or IL-12R
subunits.
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STAT6

STAT6 is activated in response to by IL-4 and IL-13. In addition, STAT6 is
essential for differentiation of Th2 cells important for humoral immunity.
Accordingly, STAT6-/- mice showed defects in IL-4-mediated functions including
Th2 helper T-cell differentiation, expression of cell surface markers, and
immunoglobulin class switching to IgE (87, 88).

STAT5

STAT5 was first isolated as a prolactin-induced transcription factor named
mammary gland factor (MGF) in mammary gland tissue (89). STAT5 consists of two
highly related genes encoding STAT5A and STAT5B proteins, which are 96%
similar at the amino acid level (90). Activated by a number of cytokines, growth
factors, and hormones, including IL-2, IL-3, IL-5, IL-7, IL-9, IL-15, GM-CSF,
thrombopoietin, erythropoietin, and growth hormone, STAT5 has been implicated in
various cellular processes, such as hematopoiesis, immunoregulation, reproduction,
and lipid metabolism. Among all the STAT family members, only STAT5 has been
demonstrated to play an essential role in regulating both T and B cell development
(90).
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Lymphoid development

All hematopoietic cells are derived from hematopoietic stem cells (HSCs).
According to a classical model, HSCs differentiate into common lymphoid
progenitors (CLPs), which give rise to both B and T cells (91), as shown in Figure 2.
Recent studies have suggested that HSCs differentiate into either common
myeloid progenitors (CMPs) or lymphoid-primed multipotent progenitors (LMPPs)
in the bone marrow (BM) (92). Myeloid cells stem from either CMPs or LMPPs,
while erythroid cells and megakaryocytes develop from CMPs (93). Lymphocytes
arise from LMPPs, which differentiate into the earliest lymphocyte progenitors
(ELPs) (94). Subsequently, ELPs differentiate into common lymphoid progenitors
(CLPs) and early thymic progenitors (ETPs) from which B and T cell development
occurs in the BM and thymus, respectively. During embryonic development,
hematopoietic stem cells arise in the aorta/gonad/mesonephros (AGM) region and
migrate to the fetal liver where hematopoiesis takes places.
As illustrated in Figure 3, thymocyte development proceeds through multiple
stages, which can be characterized by the sequential expression of cell surface
markers. The early immature T cells are CD4-CD8- double-negative (DN)
thymocytes. They can be divided into four different developmental stages, defined
based on their surface expression of CD44 and CD25 (95). Similarly, B cell
development also occurs through various stages, including CLPs, pre-proB, early
pro-B, late pro-B, pre-B, immature B and mature B cells. Each stage can be
characterized by their expression of cell-surface markers, such as B220, CD43,
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CD19, BP-1, HAS, IgM and IgD, and can be defined according to the Hardy
nomenclature (Figure 4) (96).
The development of T and B cells is tightly regulated by multiple
transcription factors and cytokines (97, 98). IL-7 (Interleukin-7) is a non-redundant
and essential cytokine for the development of both T and B cells (99). Its receptor
consists of two chains, IL-7Rand common cytokine receptor -chain (C), which
binds the Janus kinase 3 (Jak3) (100, 101). The C chain is expressed in various
hematopoietic lineages, whereas the IL-7Rsubunit is preferentially expressed in
the lymphoid system from CLPs to large pre-B and DN1-DN3 T cells as well as in
thymic and peripheral CD4+ and CD8+ single-positive (SP) T cells (102).
Binding of IL-7 to its receptor triggers activation of Jak1 and Jak3, resulting
in STAT5 activation, subsequent translocation to the nucleus and regulation of target
gene transcription (Figure 5) (103). STAT5 contains two highly related isoforms,
STAT5A and STAT5B, which are encoded by separate genes and play a critical role
in the development and function of immune cells (90).
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Figure 2. The lymphoid developmental pathway. Both B and T cells are
differentiated from hematopoietic stem cells through multiple stages including
common lymphoid progenitors, pro- and pre-B/T cells, before becoming mature B/T
cells.
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Figure 3. The T cell development pathway. T cell development proceeds through
multiple stages, which can be characterized by the sequential expression of cell
surface markers, including CD44, CD25, CD4 and CD8. The early immature T cells
are CD4-CD8- double-negative (DN) thymocytes, which can be divided into four
different developmental stages (DN1-4).
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Figure 4. The B cell development pathway. B cell development occurs through
various stages, which can be characterized by their expression of cell-surface
markers according to the Hardy nomenclature (Hardy and Hayakawa, 2001).
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Figure 5. The IL-7R signaling pathway. In unstimulated state, STAT5 resides in
the cytoplasm. Binding of ligand (IL7) to its receptor leads to phosphorylation of the
cytoplasmic tail of receptor, resulting in recruitment of STAT5 to the receptor.
STAT5 is phophorylated by JAK kinases. Phosphorylated STAT5 dimerizes and
translocates to the nucleus, where it turns on the transcription of STAT5-specific B/T
cells and then returns back to the cytoplasm.
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AIM OF THE PRESENT STUDY

SUMOylation has been shown to regulate a number of cellular processes,
including transcription, DNA repair, cell-cycle progression and signal transduction
from yeast to human (18, 19). Many transcription factors are SUMOylated, resulting
in alteration of their function (32). Previously, we reported that inactivation of the
murine SENP1 gene results in embryonic lethality prior to embryonic day 16.5
(E16.5), due to a severe defect in definitive erythropoiesis stemming from deficient
Epo production (21). SENP1 KO mouse study revealed that SENP1 controls EPO
production by regulating the stability of HIF1 (21). Despite extensive biochemical
studies on SENPs in vitro, the physiological significance and in vivo functions of the
SENPs remain poorly understood. In particular, the physiological function of SENP1
in the development of lymphoid cells has not been defined. The overall aim of my
PhD dissertation was to investigate the role of SENP1 in T and B lymphopoiesis
using SENP1 KO mice that we described earlier (21).
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RESULTS

SENP1 is highly expressed at the early stages of T and B lymphocytes

To investigate the role of SENP1 in lymphopoiesis, we first analyzed its
expression pattern in lymphoid cells. Interestingly, SENP1 was highly expressed at
the early stages of T and B cell development including DN2, DN3 and DN4 T cells
and, pro-B and Pre-B cells, respectively (Figure 6), raising the possibility that
SENP1 might participate in T and B lymphopoiesis.

SENP1 deficiency impairs T cell development

We next examined the phenotype of thymus in SENP1-/- embryos.
Histological examination of thymic sections revealed that both the size and
cellularity of E15.5 SENP1-/- thymi were markedly decreased compared with those
of wild-type littermates (Figure 7). To check whether a partial or complete block in T
cell development could explain thymic hypocellularity and smaller thymus size in
SENP1-/- embryos, we cocultured hematopoietic stem cells (HSCs) isolated from
fetal livers (FL) in E14.5 wild-type and SENP1-/- embryos with OP9 stromal cells
expressing Delta-like 1 (OP9-DL1 cells) in the presence of cytokines Flt3L (FMSlike tyrosine kinase 3 ligand) and IL-7 (Interleukin-7) to induce T cell differentiation
in vitro (104).
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Figure 6. SENP1 mRNA expression in hematopoietic lineage populations. Each
population was isolated by flow-sorting from the thymus and bone marrow of 4- to
6-week-old C57BL/6 mice. SENP1 mRNA expression was measured by quantitative
RT-PCR using TaqMan assay kit from ABI. Gene expression was normalized to 18s
rRNA level. The relative abundance is displayed as an average of triplicates of
quantitative PCR in each sample, and error bars indicate ± SD.
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Figure 7. SENP1 deficiency affects the thymic development. Hematoxylin and
eosin staining of thymic sections (top panel, original magnification: 100x and bottom
panel, original magnification: 400x) from wild-type (WT) and SENP1-/- (KO)
embryos at E15.5. The results shown are a representative of at least four independent
experiments.

28

After 7 days of co-culture, flow cytometric analysis revealed that most of the
cells derived from both wild-type and SENP1-/- HSCs were immature CD4-CD8(DN) thymocytes (Figure 8A, top panel). However, further segregation of DN
thymocytes into distinct subsets (DN1-DN4) showed an increased frequency of DN1
subset, and decreased frequencies of DN2 and DN3 subsets generated from SENP1-/HSCs (Figure 8A, lower panel). Furthermore, the absolute numbers of DN2, DN3
and DN4 T cells derived from SENP1-/- HSCs were significantly decreased
compared with those of wild-type controls (Figure 8B). These results indicate that
SENP1 is required for early T cell development at or before the DN2 stage.
Under OP9-DL1 cell co-culture conditions, wild-type and SENP1-/- HSCs
were unable to generate B and myeloid cells (Figures 9A and 9B). After 14 days of
coculture on OP9-DL1 cells, despite a substantial decrease in the absolute cell
numbers, CD4/CD8 double positive (DP), CD4 single positive (SP) and CD8 SP
could still be generated from SENP1-/- HSCs (Figure 10). These results strongly
suggest that SENP1 deficiency leads to an incomplete block in early T cell
development.
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Figure 8. SENP1 deficiency results in a severe defect in early T cell
development. (A) FL-HSCs (Lin-c-Kit+Sca1+) from wild-type (WT) and SENP1-/(KO) embryos at E14.5 were cocultured on OP9-DL1 stromal cells in the presence of
IL-7 and Flt3L. After 7 days of coculture, cells were isolated and analyzed by flow
cytometry for T cell markers CD4 and CD8 (top panel). Gated CD4-CD8- population
was further analyzed based on CD44 and CD25 (lower panel). Data shown are
representative of three independent experiments. (B) Absolute numbers of the
indicated subpopulations of thymocytes were calculated based on flow cytometry
(shown in B) and total thymocytes counts, and represented as mean ± SD; n= 5 each.
*, P<0.05; **, P<0.01; n.s. is not significant.
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Figure 9. Myeloid development in OP9-DL1 coculture. (A-B) Both wild-type and
SENP1-/- HSCs cocultured on OP9-DL1 cells were unable to generate B and myeloid
cells. Sorted FL-HSCs were cultured on OP9-DL1 stromal cells in the presence of
IL-7 and Flt3L for 7 days. Flow cytometric analysis was performed using B220 and
CD11b (A) antibodies, and CD11C and CD11b antibodies (B). Data shown are
representative of three independent experiments.
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Figure 10. T cell development in OP9-DL1 coculture after 14 days. (A-B) Wildtype and SENP1-/- FL-HSCs were cultured on OP9-DL1 stromal cells in the presence
of IL-7 and Flt3L for 14 days. T cells were analyzed by flow cytometry using CD4
and CD8 antibodies (A). Absolute cell number was counted and presented as means
± SD; n=5 each (B). **, P<0.01.
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SENP1 deficiency impairs B cell development

Next, we investigated whether B cell development is also affected by the
absence of SENP1. We first examined B lymphopoiesis in fetal livers from E14.5
SENP1-/- embryos and found that SENP1-/- embryos displayed a severe reduction in
the absolute number of B220+CD19+ B cells compared with wild-type littermate
controls (Figures 11A and 11B). To further assess the effects of SENP1 deficiency
on B cell development, we co-cultured FL-HSCs with OP9 stromal cells in the
presence of Flt3L and IL-7 to promote B cell differentiation in vitro (105). After 7
days of coculture, flow cytometric analysis revealed an increased frequency of early
pro-B (B220+CD43+BP-1-CD24+) cells generated from wild-type HSCs. In contrast,
most B cells generated from SENP1-/- HSCs displayed markers of pre-pro-B
(B220+CD43+BP-1-CD24-) and early pro-B (B220+CD43+BP-1-CD24+) cells (Figure
12A). Furthermore, the absolute numbers of pre-pro-B, early pro-B, late pro-B and
pre-B cells derived from SENP1-/- HSCs were significantly reduced compared with
wild-type controls (Figure 12B), suggesting a critical role of SENP1 at the earliest
stages of B cell development.
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Figure 11. SENP1 deficiency affects B cell development during embryonic
development. (A-B) Fetal liver cells were harvested from E14.5 wild-type and
SENP1-/- embryos. B cells were analyzed by staining with B220 and CD19
antibodies (A), absolute cell numbers of B220+CD19+ B cells were calculated and
presented as means ± SD (B); n=5 each. **, P<0.01.
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Figure 12. SENP1 deficiency results in a severe defect in early B cell
development. (A) Sorted FL-HSCs from wild-type and SENP1-/- embryos at E14.5
were cocultured on OP9 stromal cells in the presence of IL-7 and Flt3L. After 7 days
of coculture, cells were isolated and analyzed by flow cytometry for B cell markers
B220 and CD43 (top panel), CD24 and BP-1 (Gated CD43+B220+ population, lower
panel). Data shown are representative of three independent experiments. (B)
Absolute number of B cells in each developmental stage was calculated based on
flow cytometry (shown in D) and total cell number, and represented as mean ± SD;
n= 5 each. *, P<0.05; **, P<0.01; n.s. is not significant.
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Under OP9 cell coculture conditions, myeloid development was not affected
in the absence of SENP1 since the absolute number of myeloid cells derived from
both wild-type and SENP1-/- HSCs remained similar (Figures 12B and 13). After 14
days of coculture, we also found significant reductions in the frequencies and
absolute numbers of pro-B and pre-B cells (B220+CD19+) (Figures 14A and 14B),
and immature B cells (B200+IgM+) derived from SENP1-/- (Figures 14C and 14D).
These results clearly showed that SENP1 is required for B cell development at the
early stages.

SENP1 deficiency does not affect myeloid cell development

To demonstrate that the hematopoietic defects caused by SENP1 deficiency
are restricted to the erythroid (21) and lymphoid lineages, but not the myeloid
lineage, we co-cultured wild-type and SENP1-/- HSCs with OP9 stromal cells in the
presence of IL3, IL6, SCF, and Flt3L, and analyzed myeloid cells expressing Gr-1
and CD11b markers after 7 days of culture. Consistent with our previous report (21),
no defect in myeloid-lineage development was observed in the absence of SENP1
since the frequency and absolute number of myeloid cells (Gr-1+CD11b+) generated
from both wild-type and SENP1-/- HSCs were comparable (Figures 15A and 15B).
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Figure 13. Myeloid development in OP9 coculture after 7 days. Sorted FL-HSCs
from wild-type and SENP1-/- embryos at E14.5 were cocultured on OP9 stromal cells
in the presence of IL-7 and Flt3L. After 7 days of coculture, cells were isolated and
analyzed by flow cytometry for B cell marker (B220), and myeloid cell marker
CD11b. Absolute number of myeloid cells was calculated and shown in Figure 7B.
Data shown are representative of three independent experiments.
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Figure 14. B cell development in OP9-DL1 coculture after 14 days. (A-D) Wildtype and SENP1-/- FL-HSCs were cocultured on OP9 stromal cells in the presence of
IL-7 and Flt3L for 14 days. B cells were analyzed by flow cytometry using B220 and
CD19 antibodies (A), and B220 and IgM antibodies (B), and their absolute cell
numbers were calculated and presented as means ± SD (C end D, respectively); n=5
each. **, P<0.01. Data shown are representative of three independent experiments.
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Figure 15. SENP1 deficiency does not affect myeloid development. (A-B) Wildtype and SENP1-/- FL-HSCs were cultured on OP9 stromal cells in the presence of
IL3 (10ng/ml), IL6 (10ng/ml), SCF (50 ng/ml), and Flt3L (50 ng/ml) for 7 days.
Myeloid cells were analyzed by flow cytometry using indicated antibodies (A). Data
shown are representative of three independent experiments. The absolute cell
numbers of myeloid cells (Gr-1+CD11b+) were calculated based on flow cytometry
and total cell counts, and presented as means ± SD; n=5 each. n.s. is not significant
(B).
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SENP1 deficiency leads to intrinsic defects in T and B development
To further confirm that SENP1 deficiency resulted in defects that are intrinsic
to T and B cell development, we performed FL transplantation experiments using
RAG-1-/- mice, which lack mature B and T cells (106). FL cells from E14.5 wildtype and SENP1-/- embryos were transplanted into lethally irradiated RAG-1-/- mice.
Six weeks after transplantation, the lymphoid compartments of the recipients were
harvested, counted and analyzed by flow cytometry. Compared with RAG-1-/- mice
reconstituted with wild-type FL cells (wild-type recipients), the total cell numbers in
lymphoid organs of RAG-1-/- mice reconstituted with SENP1-/- FL cells (SENP1-/recipients), exhibited a 10- to 20-fold reduction (Figure 16A). Analysis of T cell
development in the thymi of recipients showed that the frequency of DP T cells in
the thymi of SENP1-/- recipients was greatly reduced compared with wild-type
recipients (Figure 16B). Similarly, analysis of B cell development in the bone
marrow of recipients revealed that the frequencies of CD19+B220+ and
B220+IgM+IgD- B cells were significantly reduced in SENP1-/- recipients (Figure
17). Taken together, our data demonstrated that SENP1 deficiency results in intrinsic
defects in T and B development.
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Figure 16. SENP1 deficiency impairs T cell development in fetal liver
transplantation experiments. (A) Cell counts in lymphoid compartments including
thymus, bone marrow, spleen and lymph node of RAG1-/- mice reconstituted with
wild-type and SENP1-/- fetal liver cells. Total cell number was calculated and
represented as mean ± SD; n= 6 each. **, P<0.01. (B) Flow cytometric analysis for T
cell markers including CD4 and CD8 in the thymi of RAG1-/- mice reconstituted
with wild-type and SENP1-/- fetal liver cells. Data shown are representative of two
independent experiments.
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Figure 17. SENP1 deficiency impairs B cell development in fetal liver
transplantation experiments. Flow cytometric analysis of B cells in bone marrow
from RAG1-/- mice reconstituted with wild-type and SENP1-/- fetal liver cells using B
cell markers B220 and CD19 (upper panel). Gated B220+ cells were further analyzed
based on IgM and IgD (lower panel). Data shown are representative of two
independent experiments.
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SENP1 regulates SUMOylation of STAT5

To check whether SENP1 deficiency may affect transcription of key
transcription factors crucial for early lymphoid development, we analyzed their
expression in fetal livers of E14.5 embryos by RT-PCR. Expression levels of PU.1,
STAT5, GATA3 and E2A from SENP1-/- fetal livers remained unchanged compared
with those from wild-type littermate controls (Figure 18). To determine whether the
impaired development of B and T cells in SENP1 deficiency is due to reduced
expression of IL-7R components, real-time PCR analysis was performed. The
mRNA levels of IL-7R components including IL-7Rα and γc chains, Jak1 and Jak3
in fetal livers of E14.4 SENP1-/- embryos were undisturbed, suggesting that the
expression of genes involved in the IL-7R signaling pathway is intact (Figure 19).
Indeed, the lymphoid defects in SENP1 deficiency described here are quite similar to
the one observed in STAT5 deficiency (107-109).
Given that SENP1 regulated activity of transcription factors (21, 22), we
therefore hypothesized that SENP1 may control early development of T and B cells
through altering the SUMOylation status of STAT5. To explore this possibility, we
first examined SUMOylation of STAT5 in wild-type and SENP1-/- B, T and myeloid
cells derived from HSC differentiation in vitro after 7 days of coculture by Western
blot analysis. As shown in Figure 20, the ~95-kDa full-length STAT5 was detected
in all wild-type and SENP1-/- B, T and myeloid cells, whereas a modified form of
STAT5 migrating at 135 kDa (~ 40 kDa shift) was observed only in SENP1-/- B and
T cells. On the other hand, the protein level of another STAT family member,
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STAT3 in SENP1-/- B and T cells was unchanged compared with wild-type B and T
cells, respectively. To verify that the ~ 135-kDa band is a SUMOylated form of
STAT5, lysates of wild-type and SENP1-/- B cells were subjected to denaturing
immunoprecipitation with anti-STAT5 antibody, followed by immunoblotting with
anti-SUMO-1 and anti-SUMO-2/3 antibodies. This ~ 135-kDa band displayed in
SENP1-/- B cells was readily detected with anti-SUMO-2/3, but not by anti-SUMO-1
or control IgG (Figure 21). These results clearly demonstrate that the modified form
of STAT5 accumulated in SENP1-/- B and T cells is indeed SUMOylated STAT5.
Consistent with the accumulation of SUMOylated STAT5, the expression of BCL-2,
a downstream target of STAT5 was markedly decreased in SENP1-/- B and T cells
compared with wild-type B and T cells, respectively (Figure 20, third panel). These
data suggest that deletion of SENP1 results in the accumulation of SUMOylated
STAT5, which alters its transcriptional activity in early B and T cells.
To further confirm that SUMOylated STAT5 can be regulated by SENP1, we
SUMOylated STAT5 by cotransfecting FLAG-tagged STAT5A or STAT5B with
HA-tagged SUMO-2 constructs in COS-1 cells. In the presence of HA-tagged
SUMO-2 construct, two major bands migrating at 115 kDa and 135 kDa were
detected (Figures 22A and 22B). In COS-1 cells, PIAS3 greatly enhanced STAT5
SUMOylation in a RING-domain-dependent manner (Figure 23). Notably,
overexpression of SENP1 completely abrogated SUMOylated STAT5, while a
SENP1 catalytic mutant (C603A mutation) could not deconjugate SUMOylated
STAT5 (Figure 24). Together, SENP1 plays a critical role in regulating the
SUMOylation state of STAT5 in vivo.
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Figure 18. The expression of key transcription factors involved in lymphoid
differentiation. RNA was isolated from fetal liver cells of SENP1+/+ and SENP1-/embryos at E14.5. RT-PCR was analyzed after normalization with b-actin. The
results shown are a representative of at least three independent experiments.

Figure 19. The expression of IL-7R components. RNA was isolated from fetal
liver cells of SENP1+/+ and SENP1-/- embryos at E14.5. Quantitative RT-PCR was
done using TagMan assay kit from ABI. Gene expression was normalized to 18s
rRNA level. The relative abundance is displayed as an average of triplicates of
quantitative PCR in each sample, and error bars indicate ± SD. The results shown are
a representative of at least three independent experiments.
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Figure 20. Modified STAT5 accumulated in SENP1-/- B and T cells. Sorted FLHSCs from wild-type and SENP1-/- embryos at E14.5 were cocultured on OP9 and
OP9-DL1 cells in the presence of IL-7 and Flt3L to differentiate into B and T cells,
respectively. After 7 days of coculture, B and T cells were isolated and lysed in
RIPA buffer. The whole cell lysates were analyzed by immunobloting with antiSTAT5 (top panel), anti-STAT3 (second panel), anti-BCL-2 (third panel), and anti-actin (bottom) antibodies. Wild-type and SENP1-/- myeloid cells derived from
HSC differentiation on OP9 stromal cells in the presence of IL3 (10ng/ml), IL6
(10ng/ml), SCF (50 ng/ml), and Flt3L (50 ng/ml) for 7 days were used as controls.
The results shown are a representative of at least three independent experiments.
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Figure 21. Endogenous STAT5 is SUMOylated by endogenous SUMO2/3 in
vivo. B cells isolated from differentiation of wild-type and SENP1-/- FL-HSCs after 7
days of coculture on OP9 cells were lysed and boiled in denaturing lysis buffer. Cell
lysates were aliquoted equally for performing immunoprecipitation (IP) by control
IgG or a mixture of anti-STAT5A and B antibodies. Bound proteins were detected
by immunoblotting (IB) with anti-SUMO2/3 (top panel), anti-SUMO1 (middle
panel) or anti-STAT5 (bottom panel) antibodies. Loading samples were
immunoblotted with anti-STAT5 or anti-actin antibodies. The results shown are a
representative of at least three independent experiments.
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Figure 22. Both STAT5A and STAT5B are SUMOylated in an overexpression
system. COS-1 cells were transfected with FLAG-tagged STAT5A (A) or STAT5B
(B) and HA-tagged SUMO-2 plasmids. Twenty four hours after transfection, cellular
protein extracts were immunoprecipitated with anti-FLAG or anti-STAT5B
antibodies followed by Western blot analysis with anti-HA (top) or anti-FLAG and
STAT5 B antibodies (bottom). The results shown are a representative of at least
three independent experiments.
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Figure 23. SUMOylation of STAT5 is enhanced by PIAS3. COS-1 cells were
transfected with 1 mg FLAG-STAT5 + 0.5 mg HA-SUMO2 + 0.5 mg Myc-PIAS3wt
or Myc-PIAS3 mut (mutant ring domain) plasmids. Twenty-four hours after
transfection, transfected cells were lysed and boiled in denaturing lysis buffer for 5
min. Protein extracts were immunoprecipitated with anti-FLAG followed by Western
blot analysis with anti-HA or anti-FLAG antibodies. The input was immunoblotted
with anti-Myc and anti-HA antibodies. The results shown are a representative of at
least three independent experiments.
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Figure 24. SENP1 de-SUMOylates SUMOylated STAT5 in vivo. COS-1 cells
were transfected with the indicated plasmids. Protein extracts were precipitated with
anti-STAT5B antibody and analyzed with HA (top) and STAT5 (bottom) antibodies.
The results shown are a representative of at least three independent experiments.
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SUMOylation inhibits tyrosine phosphorylation of STAT5

SUMOylation often, but not always, occurs on lysine residues found in the
consensus motif ΨKXE (where Ψ is any large hydrophobic residue, and X is any
residue). STAT5 has two SUMO consensus motifs at lysines 384 and 516, and four
high-scoring non-consensus motifs at lysines 71, 86, 163 and 336 (Figure 25). We
examined the ability of these sites to be SUMOylated in vivo by introducing single or
combined

mutations

(six

lysine-to-arginine

mutations).

Compared

with

SUMOylation of wild-type STAT5, SUMOylation of single mutants or combined
mutants remained unchanged, suggesting that these lysine residues are not involved
in SUMOylation of STAT5 (Figure 26). Previous studies indicate that STAT1 is
SUMOylated at lysine 703, close to tyrosine 701 (64, 110, 111). Indeed, STAT5A
contains two lysines at 696 and 700, close to tyrosine 694 (Figure 25). These lysine
residues of STAT5A/B are well conserved across species including mouse, rat and
human. SUMOylation of single mutants (K696R and K700R) or double mutant
(K696/700R) of STAT5A was drastically reduced (Figure 27A). These results
indicate that lysine residues 696 and 700 are the major sites for SUMOylation of
STAT5A in vivo. Consistently, the major SUMOylation sites in STAT5B were lysine
residues 701 and 705 (Figure 27B).
Since the SUMOylation sites are in close proximity to tyrosine, whose
phosphorylation is a prerequisite for STAT5 activation, we therefore assessed the
interplay between STAT5 phosphorylation and SUMOylation. We checked the level
of STAT5 phosphorylation in SENP1-/- B and T cells derived from HSC
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differentiation in vitro after 7 days of coculture on OP9 and OP9-DL1 cells in the
presence of IL-7 and Flt3L, respectively. Western blot analysis showed a marked
reduction of STAT5 phosphorylation in SENP1-/- B and T cells (Figure 23),
correlating

with

an

increased

SUMOylation

(Figure

20).

Notably,

the

phosphorylation of STAT5 SUMOylated form could not be detected in SENP1-/- B
and T cells. These results suggest that in the absence of SENP1, SUMOylation
inhibits STAT5 phosphorylation and that the accumulation of SUMOylated STAT5
impairs the activation–inactivation cycle of STAT5 in lymphocytes.
We further tested the effect of phosphorylation at tyrosine 694 on
SUMOylation of STAT5. Wild-type STAT5 and constitutively active STAT5 mutant
N642H were efficiently SUMOylated. In contrast, STAT5 phosphorylation mutant
Y694A abolished SUMOylation of STAT5 (Figure 29). These results strongly
suggest that SUMOylation of STAT5 requires a prior phosphorylation or nuclear
import event since the enzymes involved in SUMOylation are located in the nucleus.
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Figure 25. Schematic diagram of full-length murine STAT5 protein structure.
STAT5 contains amino terminal, coiled-coil, DNA binding, linker, SH2, and
transcriptional activation domains. Arrows indicate approximate locations of two
putative SUMO consensus motifs at lysines 384 and 516 (Ψ-K-X-E, where ψ
represents a large hydrophobic amino acid (A, F, I, L, M, V, W) and X represents
any amino acid), and four other non-consensus motifs at lysines 71, 86, 163 and 336.
Two lysine residues 696 and 700 located close to Y694 and Y699 of STAT5A and
STAT5B respectively are underlined.
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Figure 26. STAT5 is not SUMOylated at lysine residues within the SUMO
consensus motifs. COS-1 cells were transfected with FLAG-tagged STAT5A and its
mutants along with HA-SUMO2 plasmids. Protein extracts were immunoprecipitated
with anti-FLAG and then revealed by Western blot analysis with antibodies to antiHA (top) and anti-FLAG (bottom). 5KR: 5 lysine-to-arginine mutations at positions
71, 86, 336, 384, and 516. 6KR: 6 lysine-to-arginine mutations at positions 71, 86,
163, 336, 384, and 516. The results shown are a representative of at least three
independent experiments.
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Figure 27. mapping STAT5 SUMOylation sites. (A) STAT5A is modified by
SUMO at lysine residues 696 and 700. COS-1 cells were transfected with FLAGtagged STAT5A and its mutants along with HA-SUMO2 plasmids. Protein extracts
were immunoprecipitated with anti-FLAG and then revealed by Western blot
analysis with antibodies to anti-HA (top) and anti-FLAG (bottom). The results
shown are representative of at least three independent experiments. (B) Identification
of SUMOylation sites in STAT5B. COS-1 cells were transfected with STAT5B and
its mutants along with HA-SUMO2 plasmids. Immunoprecipitates of STAT5B were
immunoblotted with anti-HA (top) or anti-STAT5B antibodies (bottom). The results
shown are a representative of at least two independent experiments.
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Figure 28. Tyrosine phosphorylation of STAT5 is diminished in SENP1-/- B and
T cells. Sorted FL-HSCs from wild-type and SENP1-/- embryos at E14.5 were
cocultured on OP9 and OP9-DL1 cells in the presence of IL-7 and Flt3L to
differentiate into B and T cells, respectively. After 7 days of coculture, B and T cells
were isolated and lysed in RIPA buffer. The whole cell lysates (prepared and
analyzed in Fig. 3A) were further analyzed by immunobloting with anti-P-STAT5
(top panel) and anti--actin (bottom) antibodies. The results shown are a
representative of at least three independent experiments.
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Figure 29. SUMOylation of STAT5 is tyrosine phosphorylation-dependent.
COS-1 cells were transfected with FLAG-tagged STAT5A (wild-type), STAT5
phosphorylation mutant Y694A (mutation of tyrosine 694 to alanine) and
constitutively active STAT5 mutant N642H, and HA-tagged SUMO-2 plasmids.
Twenty four hours after transfection, Cellular protein extracts were
immunoprecipitated with anti-FLAG antibody followed by Western blot analysis
with anti-HA (top) or anti-FLAG antibodies (bottom). The results are a
representative of at least three independent experiments.
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SENP1 controls an acetylation/SUMOylation switch in STAT5
To further understand the effect of SUMOylation on STAT5-mediated
transcriptional activity, we compared wild-type and SUMOylation-deficient
STAT5A for their ability to activate transcription in reporter assays. STAT5deficient MEF cells stably expressing wild-type STAT5A and its mutants were
transiently transfected with a luciferase reporter pGL4--Casein. Compared with
wild-type STAT5A, STAT5A(K700R) exhibited a similar transactivation activity,
suggesting that SUMOylation of STAT5A at lysine 700 did not play a role in
transcription regulation (Figure 30). However, STAT5A(K696R) or STAT5A(K696700R) showed a markedly decreased in transactivation activity, raising an intriguing
possibility that lysine 696 may also be subjected to another form of post-translational
modification.
Lysine residues can be targeted by multiple modifications, such as
ubiquitination, SUMOylation, methylation, and acetylation. The carboxy-terminal
transactivation domain of STAT5 is known to interact with the histone
acetyltransferase p300/CBP, resulting in enhanced STAT5-dependent transcription
(112). We hypothesized that lysine 696 is also a target for acetylation. To test this
possibility, we first checked whether STAT5 can be acetylated by p300.
Coexpression of p300 in HEK-293 cells significantly enhances STAT5A acetylation
(Figure 31). Wild-type STAT5A and STAT5A(K700R) mutant, but not
STAT5A(K696R) and STAT5A(K696-700R) mutants, were acetylated, suggesting
that lysine 696 is also a major acetylation site (Figure 32). Consistent with our data, a
recent study indicates that STAT5B acetylation on lysine residues including lysine
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701 (corresponding lysine 696 on STAT5A) is essential for STAT5B dimerization
since mutation of lysine 701 to arginine impaired STAT5B dimerization and
transcriptional activity (57).
Next, we assessed endogenous STAT5 acetylation in wild-type and SENP1-/FL cells. Protein extracts were immunoprecipitated with anti-STAT5 antibody and
analyzed by immunoblotting with antibody specific for K701-acetylated STAT5B.
As shown in Figure 33, endogenous STAT5 was acetylated in both wild-type and
SENP1-/- FL cells treated with IL-7. Notably, STAT5 acetylation in IL7-treated
SENP1-/- FL cells was significantly decreased compared with that of IL7-treated
wild-type FL cells, suggesting that SENP1 regulates the acetylation status of STAT5.
To confirm the role of SENP1 in the regulation of STAT5 acetylation and
SUMOylation, HEK-293 cells were transfected with FLAG-tagged STAT5A, MYCtagged SUMO3, HA-tagged p300 in the presence of RGS-tagged SENP1 or RGStagged SENP1 mutant plasmids. Overexpression of SENP1 enhanced acetylation and
inhibited SUMOylation of STAT5A (Figure 34). In contrast, overexpression of
SENP1 mutant decreased acetylation and enhanced SUMOylation of STAT5 (Figure
34). Taken together, these results demonstrate that SENP1 plays a critical role in
regulating an acetylation/SUMOylation switch in STAT5.
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Figure 30. The K696R mutant of STAT5 impairs its transcriptional activity.
STAT5A/B-deficient MEFs, infected with an empty lentiviral vector (control, CT) or
lentiviral vectors directing expression of wild-type STAT5, STAT5K696R,
STAT5K700R or STAT5K696-700R, were transiently transfected with a luciferase
reporter (pGL4-b-Casein) in triplicates. After 6-hour transfection, the cells were
cultured in serum-free medium in the presence or absence of GH (200 ng/ml) for 18
hours. Samples were harvested and evaluated for luciferase and renilla activity. The
fold induction was calculated as the ratio of luciferase activity in the presence and
absence of GH. Data shown are representative of three independent experiments.
Error bars indicate standard deviation. The lower panel shows STAT5 expression
levels in different clones measured by Western blot analysis with anti-FLAG and
anti-b-actin (control) antibodies.
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Figure 31. STAT5 is acetylated by p300. HEK-293 cells (in 6-well plate) were
transfected with indicated FLAG-tagged STAT5A and HA-tagged p300 plasmids.
Immunoprecipitation was performed with EZview Red ANTI-FLAG M2 Affinity
Gel beads and analyzed with anti-acetyl lysine (top panel) and anti-FLAG (second
panel) antibodies. The results are a representative of at least three independent
experiments.
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Figure 32. Lysine 696 is also a target for acetylation. Lysates from HEK-293 cells
transfected with plasmids expressing FLAG-tagged STAT5A or SUMOylationdeficient mutants of STAT5A and HA-p300 were immunoprecipitated with EZview
Red ANTI-FLAG M2 Affinity Gel beads and analyzed with the indicated antibodies.
The results are representatives of at least three independent experiments.
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Figure 33. Endogenous STAT5 is acetylated in FL cells treated with IL-7. FL
cells isolated from three to five E14.5 wild-type and SENP1-/- embryos were treated
with IL-7 for 10 min and lysed in RIPA buffer. Cellular extracts were
immunoprecipitated with anti-STAT5 antibody and analyzed with anti-aK701STAT5B (top panel) and anti-STAT5 (second panel) antibodies. Loading samples
were immunoblotted with anti-actin antibody. The results shown are a
representative of three independent experiments.
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Figure 34. SENP1 regulates the SUMOylation/acetylation status of STAT5.
Lysates from HEK-293 Cells (in 6-well plate) transfected with plasmids expressing
FLAG-tagged STAT5A, MYC-tagged SUMO3, HA-tagged p300 and RGS-tagged
SENP1w (wild-type) or RGS-tagged SENP1m (mutant) were immunoprecipitated
with EZview Red ANTI-FLAG M2 Affinity Gel beads and analyzed with anti-acetyl
lysine (top panel), anti-SUMO2/3 (second panel) and anti-FLAG (third panel)
antibodies. The input was immunoblotted with anti-RGS, anti-Myc and anti-HA
antibodies. The results shown are a representative of at least three independent
experiments.
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DISCUSSION

SENP1 is essential for early lymphoid development
SUMOylation has emerged as an important regulatory mechanism for protein
function (13, 19). SENPs are essential for reversing SUMOylation in many different
systems, but the physiological functions of SENPs are poorly understood. Recently,
SENP1 has been shown to play a crucial role in regulating erythropoiesis (20-22).
However, the physiological function of SENP1 in the development of the immune
system remains unknown. In the present study, we have discovered that SENP1 is
essential for early T and B lymphopoiesis.
The IL-7/IL-7R signaling pathway plays a critical role in regulating T and B
cell development by controlling several cellular processes, such as cell survival,
proliferation and VDJ recombination through alteration of chromatin structure. Loss
of IL-7R, C or Jak3 gene in mice leads to a severe developmental block of T and
B cells (113-117), and mutations of these genes results in severe combined
immunodeficiency in humans (118-121). IL-7 signaling is required for early T cell
development in the thymus, mainly to protect cells at the DN 2 and DN3 stages from
apoptotic cell death by regulating the expression of the survival proteins Bcl-2 and
Mcl-1. Two groups independently crossed IL-7R-deficient mice to mice expressing a
Bcl2 transgene. As a result, enforced expression of BCL-2 was sufficient to partially
restore T cell development but was unable to rescue B cell development in IL-7Rdeficient mice (122-124). These studies suggested that the IL-7R signaling not only
promote pro-B cell survival, but also regulates the expression of other genes required
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for B cell development. Consistent with this notion, a recent study indicates that IL7R signaling is required for stage transition in adult B cell development through upregulation of the early B cell transcription factor EBF (125).
The transcription factor STAT5 is a key molecule downstream of The IL7/IL-7R signaling pathway. Earlier analysis of STAT5 knockout mice (STAT5ABΔN/ΔN
mice), which express N-terminally truncated and partially functional STAT5
proteins, revealed only a mild defect in T and B cell development (126-128).
However, a complete inactivation of STAT5A/B in mice (STAT5ABnull/null mice)
exhibited a profound defect in early T and B cell development (107-109). These
studies clearly indicate the importance of STAT5 in regulating early T and B cell
development. Our data indicate that SENP1 deficiency results in severe defects in
early T and B cell development, similar to that observed in STAT5ABnull/null mice,
suggesting that STAT5 may be a direct target of SENP1. In agreement with this
hypothesis, we also found that BCL-2, a key downstream target of STAT5 is
significantly downregulated in SENP1-/- T and B lymphocytes.
A possible explanation for the impaired development of both T and B cells
observed in SENP1-/- embryos could be decreased numbers or function of HSCs.
However, we have previously reported that HSCs were not affected in SENP1-/embryos (21). Consistent with our previous findings, myeloid development is not
affected in SENP1 deficiency. We also observed that SENP1 is expressed very high
in HSCs (Figure 6). This suggests that SENP1 may be required for long-term selfrenewal capacity of HSCs. Future studies are needed to address this important issue.
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STAT5 is regulated by the SUMOylation pathway
PIAS proteins were initially identified as negative regulators of STAT
signaling that inhibit the activity of STAT-transcription factors (58, 59). The exact
molecular mechanisms by which the PIAS proteins inhibit STAT activity remain
unclear, although several models have been proposed. For example, PIAS proteins
bind only to activated STAT dimmers in the nucleus and inhibit their DNA-binding
activity. Other possible explanation for the role of PIAS proteins in the regulation of
STAT activity is that PIAS protein can recruit other co-regulators, including histone
deacetylases (HDACs), to repress transcription. A recent study reported that PIAS1
binding to the Foxp3 promoter leads to recruitment of DNA methyltransferases and
heterochromatin protein 1 for epigenetic modifications (61). Pias1 deficiency results
in promoter demethylation, reduced histone H3 methylation at Lys9, and enhanced
promoter accessibility. Interestingly, deletion of PIAS1 leads to the enhanced
binding of STAT5, a key transcription factor involved in Foxp3 induction to the
Foxp3 promoter. As a result, PIAS1-/- mice exhibit the increased frequency of
Foxp3+ CD4+CD8+ thymocytes (61). In deed, SUMOylation of many transcription
factors results in alterations of their localization or interaction with binding partners.
In most cases, SUMOylated proteins suppress transcription, possibly due to their
interaction with co-repressors. Thus, the mechanism that SUMOylation regulates
transcription is quite similar to that a PIAS protein suppresses the transcriptional
activity of transcription factors. It is likely that PIAS proteins regulate the
transcriptional activity of transcription factors through the SUMOylation pathway.
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PIAS proteins have SUMO-specific E3 ligase activity, and have been shown
to promote the SUMOylation of numerous transcription factors, such as p53, LEF1
and c-Jun (129-131). These studies raised the possibility that STAT activity might be
regulated by the SUMOylation pathway. It was previously shown that STAT1 are
SUMOylated on Lysine 703 in an overexpression system (63, 64, 111). However, the
in vivo function of SUMOylation in the regulation of STAT1 activity remains
unclear. In addition, it is not known whether other STATs can be modified by
SUMO. In this study, we found that SUMOylation negatively regulates STAT5
activity. The accumulation of SUMOylated STAT5 results in suppression of STAT5
activity and subsequent signaling events in SENP1-/- T and B cells. Although we also
found that STAT5 SUMOylation is greatly enhanced by PIAS3 in an overexpression
system, further studies will be required to define whether this SUMO-specific E3
ligase is involved in regulation of STAT5 activity in vivo.

SENP1 regulate STAT5 SUMOylation
Protein function is tightly regulated by reversible posttranslational
modifications to create an on and off state that is crucial for many biological
processes. Many proteins are dynamically modified at multiple sites by different
modifications (26). The histone code hypothesis has been proposed that distinct
histone modifications, on one or more tails, act alone, sequentially or in combination
to form a 'histone code' that is then read by effector proteins to bring about distinct
downstream events (132). On the histone H3 tail, lysines 9 and 27 are well-known
methylation sites, and methylation of these sites is ‘read’ by heterochromatin protein
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1 (HP1) and Polycomb (Pc), leading to heterochromatin-mediated gene silencing
(Lys 9) and epigenetic repression (Lys 27), respectively (133, 134). It is noteworthy
that lysines 9 and 27 are located the “RK9S” or “RK27S” motif. According to the
“methyl/phos switch” model, serine phosphorylation of the “RKS” motif that
engages an HP1 or Pc module could lead to consecutive loss of binding (44).
The interplay between phosphorylation and SUMOylation of neighboring
sites has been shown to play an important role in regulating the transcriptional
activity of many transcription factors. For example, heat-shock factors (HSFs),
GATA-1 and myocyte enhancer factor 2 (MEF2), containing a SUMO consensus site
and an adjacent proline-directed phosphorylation site (ΨKxExxSP), are regulated by
phosphorylation-dependent SUMOylation (27, 28, 135). The motif ΨKxExxSP
couples sequential phosphorylation and SUMOylation and has been referred to as a
“Phospho-SUMOyl switch” (26). It has been shown that STAT1 SUMOylation at
lysine 703 inhibits its phosphorylation at tyrosine 701 (136). In addition, STAT1
SUMOylation at lysine 703 and STAT1 phosphorylation at tyrosine 701 are mutually
exclusive (137). We have identified two SUMOylation sites of STAT5 at lysines 696
and 700, located in close proximity to tyrosine 694, whose phosphorylation is a
prerequisite for STAT5 activation, suggesting a possible interplay between
SUMOylation and phosphorylation in regulating STAT5 activity. Indeed,
SUMOylation

of

STAT5

is

phosphorylation-dependent,

since

STAT5

phosphorylation mutant Y694A abolished SUMOylation of STAT5 (data not
shown). We also found that SENP1 deficiency causes increased STAT5
SUMOylation, correlating with diminished STAT5 phosphorylation and activity in
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lymphocytes (Figures 20 and 28), suggesting that SUMOylation of STAT5 inhibits
its phosphorylation and subsequent signaling events. Interestingly, SUMOylation of
STAT5 observed in the absence of SENP1 appears to be lymphocyte specific, since
no SUMOylated STAT5 could be detected in SENP1-/- myeloid cells (Figure 20).
Further investigations are required to resolve this issue.

The acetylation/SUMOylation switch in STAT5 is regulated by SENP1
Since lysine can be a target of different posttranslational modifications,
SUMOylation can block alternative lysine-targeted modifications, such as
ubiquitination, methylation or acetylation. It was previously reported that IκBα is
SUMOylated on K21, which is also targeted by ubiquitination (29). Transcriptional
activity of several transcription factors, such as SP3, HIC1 and MEF2A can be
regulated by interplay between SUMOylation and acetylation on the same lysine
residue (30, 31, 138). An acetylation-SUMOylation switch on MEF2 is further
regulated by its phosphorylation (31). In addition to tyrosine phosphorylation,
acetylation of different STATs has been shown to play a critical role in regulating
their activity (52, 53, 55, 56). For example, STAT3 acetylation at lysine 685 is
essential for its dimerization and transcriptional activity (55). Here, our data clearly
show that STAT5A is acetylated at lysine 696, which is also a target for
SUMOylation. Acetylation of STAT5 at lysine 696 is essential for STAT5
activation, since mutation of this lysine diminished the transcriptional activity of
STAT5 (Figure 30). Consistent with our finding, a recent study has reported that
STAT5B acetylation on lysine 701 (corresponding lysine 696 on STAT5A) is
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essential for STAT5B dimerization and transcription (57). Notably, our data provide
direct evidence that SENP1 regulates an acetylation/SUMOylation switch in STAT5.

Proposed model
Based on the findings reported here, we propose a model for the role of
SENP1 in the regulation of an acetylation-SUMOylation switch in STAT5 (Figure
35). In unstimulated cells, STAT5 exists in the cytoplasm as a monomer. Upon
activation, tyrosine-phosphorylated and acetylated STAT5 dimerizes, translocates to
the nucleus, and activates transcription. We currently do not know which signal
induces the acetylation/SUMOylation switch in STAT5. Since we did not observe
the phosphorylation of STAT5 SUMOylated form in SENP1-/- B and T cells (Figure
20), it seems likely that dephosphorylation of STAT5 promotes a switch from
acetylation (active state) to SUMOylation (inactive state). It is also possible that
SUMOylation of STAT5 facilitates its dephosphorylation. SENP1 protein, which is
predominantly present in the nucleus (16), is required for de-conjugating
SUMOylated STAT5 before it returns to the cytoplasm to complete an activationinactivation cycle. In the absence of SENP1, STAT5 is accumulated in the
SUMOylation state, leading to inhibition of STAT5 phosphorylation and acetylation,
and subsequent signaling events. Thus, our findings establish a specific role of
SENP1 in regulating lymphoid development via an acetylation/SUMOylation switch
in STAT5.
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Figure 35. A model for the role of SENP1 in the regulation of acetylationSUMOylation switch in STAT5. SUMOylation switches STAT5 from an active
state to an inactive state. SENP1 is required to remove SUMO from conjugated
STAT5, allowing it to re-enter the activation-inactivation cycle. * is lysine 696 in
STAT5A or lysine 701 in STAT5B; A is acetylation; P is phosphorylation.
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In conclusion, our study has provided evidence that SENP1 controls early T
and B lymphopoiesis through the regulation of an acetylation/SUMOylation switch
in STAT5. SENP1 deficiency results in severe defects in early T and B cell
development. Our data clearly demonstrate that SENP1 regulates STAT5 activity via
an acetylation/SUMOylation switch in STAT5. SENP1 deficiency causes the
accumulation of SUMOylated STAT5, thus preventing STAT5 to re-enter another
activation-inactivation cycle, which contributes to defective early T and B cell
development. The acetylation/SUMOylation switch may acts as an important
mechanism involving in the regulation of transcription in the immune system to turn
the signaling ON and OFF in response to cytokines or pathogens.
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MATERIALS AND METHODS
Mice
The generation and screening of SENP1-/- fetuses has been described
previously (21). SENP1+/- mice were intercrossed, and E14.5 fetuses (date of plug =
E0.5) were obtained for FL isolation. RAG1-/- mice were obtained from The Jackson
Laboratory. All animal protocols used in this study were approved by the
Institutional Animal Care and Use Committee at The University Texas M. D.
Anderson Cancer Center.

Plasmids
The full-length cDNA of murine STAT5A was amplified from the retroviral
vector pMIG-STAT5 (a gift of Drs. Yong-Jun Liu & Stephanie S. Watowich, UTMD Anderson cancer center), and then subcloned into p3xFLAG-CMV™-7.1
Expression Vector (Sigma, St Louis, MO) using standard techniques. Rat STAT5b
pcDNA3.1- was a kind gift from Dr. L.-Y. Yu-Lee (Baylor College of Medicine).
Myc-tagged wild-type mouse PIAS3 and Myc-tagged mouse PIAS3 RING domain
mutant were generously provided by Dr. Fang Liu (Rutgers University). pGL4
mouse -Casein reporter plasmid was kindly given by Dr. Koichi Ikuta (Kyoto
University). pGL4.74 [hRluc/TK] vector was from Promega. HA-p300 plasmid was
described earlier (139). HA-SUMO2, Flag-SENP1, and Flag-SENP1 catalytic mutant
plasmids were generated in our laboratory. STAT5 mutants were generated by using
a QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA).
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Antibodies and Cytokines
Anti–Flag (M2, F3165) was from Sigma. Anti–HA (influenza hemagglutinin)
(16B12, MMS-101P) was from Covance. Anti-RGS (34610) was from QIAGEN.
Anti-Myc (9E10) was from Santa Cruz Biotechnology. Monoclonal anti-SUMO-1
antibody (anti-GMP-1) was from Zymed. Anti-SUMO-2/3 was purchased from
Abgent. Anti-STAT5 (C-17) and anti-STAT3 (C-20) antibodies were from Santa
Cruz Biotechnology. Antibodies for STAT5A and STAT5B were from R&D
Systems. Anti-phospho-STAT5 was from cell Signaling. Anti-Bcl-2 antibody
(610538) was from BD Biosciences. Anti-acetylated-lysine antibody (9441s) was
from Cell Signaling. Anti-aK701-STAT5b was from Dr. Y. Eugene Chin (Brown
University) and described previously (57). Anti--Actin was from Sigma.
All cytokines, including murine IL-7, murine Ilt3 ligand, murine IL-3, murine
IL-6 and murine SCF, were purchased from Peprotech (Rocky Hill, NJ).

Monoclonal antibodies and flow cytometry
All monoclonal antibodies used in this study were from BD Pharmingen:
anti-c-Kit (2B8; APC), anti-Sca-1 (E13-161.7; PE and D7; FITC), anti-TER-119
(TER-119; FITC, APC, PE), anti-CD11b (M1/70; FITC), anti-Gr-1 (RB6-8C5;
PerCP-Cy5.5), anti-CD19 (1D3; PerCP-Cy5.5), anti-CD4 (RM4-5; PerCP-Cy5.5 and
GK1.5; FITC), anti-CD8a (53-6.7; PerCP-Cy5.5, APC), anti-CD44 (Pgp-1; FITC,
IM7; APC), anti-CD25 (7D4; FITC, PE), anti-mouse early B lineage (AA4.1; FITC),
anti-CD24 (M1/69; FITC), anti-BP1 (6C3; PE, biotin), anti-CD43 (S7; FITC, biotin),
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anti-B220 (RA3-6B2; APC, PE), anti-IgM (II/41; APC). For detection biotinated
antibodies, streptavidin-APC and PerCP-Cy5.5 (BD Pharmingen) were used.
Single-cell suspensions were first incubated on ice with rat anti-mouse
CD16/CD32 (BD PharMingen) to block nonspecific binding to Fc receptors.
Subsequently, cells were incubated with indicated antibodies and analyzed using a
LSR II flow cytometer or FACS-Calibur machine and the FlowJo analyzing software
(Treestar).

Purification of FL-HSCs
E14.5 fetal liver cells were harvested and treated with red blood cell lysis
buffer (Sigma). Then, cells were stained with anti-c-Kit-APC and anti-Sca-1-PE
antibodies, and a mixture of antibodies to lineage markers: Gr-1, CD11b. TER-119,
CD19, CD4 and CD8. FL-HSCs (lin- c-KithighSca-1high) were sorted using FACSAria
cell sorter (BD Biosciences).

B and T cell differentiation in vitro
OP9 and OP9-DL1 stromal cell lines (generous gifts from Dr. Juan Carlos
Zúñiga-Pflücker, University of Toronto, Toronto, Canada) were co-cultured as
previously described (104). Briefly, stromal cells were maintained in alpha-MEM
(Gibco BRL) containing 20% FBS (Gibco BRL) and penicillin–streptomycin
(Sigma-Aldrich). Wild-type and SENP1-/- FL-HSCs (1000-3000 cells/well in 24-well
plates) were placed on OP9 and OP9-DL1 monolayers, for B and T lineage
differentiation, respectively. Co-culture media contained: alpha-MEM, 10% FBS, 10
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mM HEPES (Gibco BRL), 1 mM sodium pyruvate (Gibco BRL), 2 mM GlutaMax,
penicillin–streptomycin, 50 mM 2-mercaptoethanol, 5 ng/ml IL-7 and 5 ng/ml Flt3L.
After 4 days of culture, the cells were passed onto newly prepared OP9 and OP9DL1 cells. For myeloid differentiation, wild-type and SENP1-/- FL-HSCs were
placed on OP9 monolayers in the presence of IL3 (10ng/ml), IL6 (10ng/ml), SCF (50
ng/ml) and Flt3L (50 ng/ml).

Transplantation experiments
Two x 106 fetal liver cells isolated from E14.5 wild-type and SENP1-/embryos were injected intravenously into lethally (950 rad) irradiated RAG-1deficient mice. Mice were sacrificed 5-6 weeks after transplantation. The lymphoid
compartments of the recipients were analyzed by flow cytometry. The experiments
shown in this study represent results from two independent experiments.

RNA Extraction and real time PCR assay
Total RNA was extracted using the RNeasy Mini Kit from QIAGEN and
converted into cDNA using Advantage RT-for-PCR Kit (Clontech) according the
protocols described in the handbooks. Quantitative RT-PCR were performed using
TagMan gene expression assay from (Applied Biosystems) and analyzed on the
GeneAmp 7700 sequence detection system (Applied Biosystems). Gene expression
was normalized to 18s rRNA level. The relative abundance is displayed as an
average of triplicates of quantitative PCR in each sample, and error bars indicate ±
SD. All primers were purchased from Applied Biosystems: mouse SENP1
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(Mm00522968_m1), mouse interleukin 7 receptor (Mm00434295_m1), mouse Janus
kinase 3 (Mm00439962_m1), mouse Janus kinase 1(Mm00600614_m1), mouse
interleukin 2 receptor gamma chain (Mm00442885_m1), eukaryotic18s rRNA
(4319413E).
RT-PCR was performed using gene specific primers: PU1, E2A and GATA3
(140). The primers for STAT5 and -Actin were described previously (21).

Luciferase assays
STAT5 and its mutants were constructed in pCDH-T2AcGFP-MSCV
(System Biosciences). The lentiviruses were generated according to the
manufacturer's protocol (System Biosciences). STAT5A/B-deficient MEFs (a kind
gift from Dr. James N. Ihle at the St. Judes Childrens Research Hospital) infected
with an empty lentiviral vector (control) or lentiviral vectors directing expression of
wild-type STAT5A and its mutants including STAT5K696R, STAT5K700R or
STAT5K696-700R, were transiently transfected with luciferase reporter (pGL4-Casein) and pGL4.74 [hRluc/TK] plasmids in triplicate using FuGENE HD (Roche).
After 6-hour transfection, the cells were cultured in serum-free medium in the
presence or absence of GH (200 ng/ml) for 18 hours. Samples were harvested and
evaluated for luciferase and renilla activity. The fold induction was calculated as the
ratio of luciferase activity in the presence and absence of GH. Data are representative
of three independent experiments. Error bars indicate standard deviation.

Western blot analysis
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B, T and myeloid cells derived from HSC differentiation on day 7 of
coculture with OP9 cells and OP9-DL1 cells were harvested and filtered through a
70-µm filter to exclude pieces of disrupted monolayer. After washing twice with icecold PBS, the cells were lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1%
Triton X-100, 1% Sodium deoxycholate , 0.1 % SDS, [pH 7.5]) supplemented with
complete protease inhibitor cocktail and 20 mM N-Ethylmaleimide (NEM,
Sigma).Whole-cell protein extracts were prepared and quantified by the Bradford
method (Bio-Rad, Hercules, CA). Equal amounts of protein (20 g/lane) was
electrophoretically separated on SDS-PAGE and transferred to a PVDF membrane.
The membranes were blotted with indicated antibodies. An anti-rabbit or anti-mouse
antibody conjugated to horseradish peroxidase was used as secondary antibodies, and
the signal was detected using a chemiluminescence kit (PerkinElmer, Wellesley,
MA).

Immunoprecipitation
For in vivo SUMOylation assay, COS-1 cells were transfected with indicated
plasmids. At 24 hr after transfection, cells were lysed with immunoprecipitation
buffer (10 mM phosphate buffer, 10 mM Tris, 150 mM NaCl, 1% Triton X-100, and
20 mM NEM [pH 7.5]) containing a protease inhibitor cocktail, and
immunoprecipitated with the indicated

antibodies or EZview Red Affinity Gel

matrix (Sigma, St. Louis, MO). For in vivo acetylation assay, HEK-293 cells were
transfected with indicated plasmids. After 48-hour transfection, cells were lysed in
RIPA buffer containing a protease inhibitor cocktail, 10 mM nicotinamide and
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500nM trichostatin A, and immunoprecipitated with the indicated antibodies. For
denaturing immunoprecipitation, the cells were lysed in 0.2 ml denaturing IP buffer
(1% SDS, 50 mM Tris, 10 mM DTT, [pH 7.5]) and boiled for 5 minutes.
Subsequently, denatured proteins were diluted in immunoprecipitation buffer and
immunoprecipitated with the indicated antibodies. Immunoprecipitated proteins were
resolved by SDS/PAGE and analyzed by immunoblotting.

Statistical analysis.
Data are presented as mean ± one standard deviation (SD); p values were
calculated using an unpaired two-tailed Student’s t test in the Microsoft Excel
software. P > 0.05 was considered to be not significant; *, P < 0.05 and **, P < 0.01
means significant and very significant, respectively.
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